• Gamithromycin (BA1074): PK/PD Precision and Clinical Breakpo

  2026-07-27

  Explore Gamithromycin's advanced PK/PD targets and clinical breakpoint determination for Streptococcus suis, with unique insights from recent research. This article offers a practical guide for dose optimization and experimental design, setting it apart from standard protocol reviews.

• Cefodizime: Third-Generation Cephalosporin for Advanced Anti

  2026-07-27

  Cefodizime stands out as a third-generation cephalosporin antibiotic with robust activity against both Gram-positive and Gram-negative pathogens, making it indispensable for resistance modeling and translational infectious disease research. This guide details optimized workflows, protocol parameters, and troubleshooting strategies—empowering microbiology researchers to harness its broad-spectrum and immunomodulatory potential.

• Ultra Fast LC-MS/MS for Cefazedone–Etimicin PK Analysis in B

  2026-07-26

  This study introduces a validated ultra fast liquid chromatography–tandem mass spectrometry (UFLC–MS/MS) method for simultaneous quantification of cefazedone and etimicin in beagle dog plasma. The protocol enables precise pharmacokinetic evaluations of single and combination antibiotic therapies, informing optimal dosing and clinical translation.

• Primary Antibody Dilution Buffer: Reliable Immunoassay Resul

  2026-07-25

  This article addresses real laboratory challenges in cell-based immunoassays, demonstrating how the Primary Antibody Dilution Buffer (SKU K1200) improves reproducibility and sensitivity. By integrating scenario-driven Q&A and evidence-based guidance, it highlights workflow optimizations and vendor selection for reliable antibody-based detection.

• Network-Based Identification of Apigenin for Alzheimer’s Dis

  2026-07-24

  A recent network medicine framework systematically identified apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) as a leading neuroprotective flavonoid candidate for Alzheimer’s disease. The study combines computational and cellular models to clarify apigenin’s mechanisms, emphasizing apoptosis and neuroinflammation modulation and highlighting methodological advances relevant for translational research.

• p53 Status Modulates ERCC1-Deficient Lung Cancer Response to

  2026-07-24

  Heyza et al. elucidate how p53 status profoundly alters the viability of ERCC1-deficient lung cancer cells following interstrand crosslink (ICL) damage, revealing synthetic viability mechanisms that complicate the predictive value of ERCC1 as a biomarker for platinum chemotherapy response. This mechanistic insight has significant implications for biomarker-driven therapy selection and the study of DNA repair vulnerabilities in cancer.

• Anlotinib Hydrochloride: Redefining Anti-Angiogenic Research

  2026-07-23

  This article provides translational researchers with an advanced, mechanism-rich perspective on deploying Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in cancer research. It integrates preclinical insights, experimental protocols, comparative TKI analysis, and strategic translational guidance—bridging the gap between bench discovery and clinical innovation.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-07-23

  Schwartz's dissertation advances the evaluation of anticancer compounds by distinguishing between relative and fractional viability in in vitro models. This distinction enables more accurate interpretation of drug effects, improving assay design and translational relevance for cancer research.

• Cefiderocol’s In Vitro Efficacy Against Resistant P. aerugin

  2026-07-22

  The referenced study provides the first large-scale, direct comparison of cefiderocol and β-lactam/β-lactamase inhibitor combinations against European Pseudomonas aeruginosa and Acinetobacter spp. isolates, including those resistant to meropenem. Its findings clarify cefiderocol’s superior in vitro activity, informing both resistance surveillance and experimental design for antimicrobial research.

• Gamithromycin (BA1074): PK/PD Precision and Dose Optimizatio

  2026-07-22

  Explore the advanced pharmacokinetic and pharmacodynamic principles of Gamithromycin (ML-1709460) for veterinary respiratory models. This article uniquely guides researchers in dose selection and assay design, bridging evidence from recent in vivo studies to practical laboratory implementation.

• Protease Inhibitor Cocktail EDTA-Free: Advanced Protein Extr

  2026-07-21

  Unlock high-fidelity protein extraction and post-translational analysis with the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO). Its EDTA-free formulation preserves divalent cations, making it ideal for phosphorylation studies and sensitive enzyme assays. Learn how to maximize integrity and reproducibility in cutting-edge research workflows.

• Nitrocefin in Colorimetric β-Lactamase Assays: Practical Wor

  2026-07-21

  Nitrocefin stands out as a gold-standard chromogenic cephalosporin substrate, enabling rapid, quantitative assessment of β-lactamase activity and antibiotic resistance. This guide delivers actionable workflows, troubleshooting insights, and a translation of recent in silico screening advances, empowering researchers to streamline inhibitor discovery and resistance profiling with robust, reproducible results.

• FAST: Food-Grade Nanoparticle Assembly for Nutraceutical Del

  2026-07-20

  This study introduces Facilitated Self-Assembling Technology (FAST) as an innovative, food-grade method for generating stable, bioavailable nutraceutical nanoparticles without synthetic surfactants or organic solvents. The approach enables efficient, scalable delivery of hydrophobic bioactives such as curcumin and resveratrol, paving the way for safer and more effective nutritional supplements.

• Metal-Ion-Chelating l-Phe Nanostructures Enhance ICB Efficac

  2026-07-20

  This study introduces metal-ion-chelating l-phenylalanine nanostructures that, in combination with short-term starvation, remodel the immunosuppressive tumor microenvironment and enhance dendritic cell activation, thereby improving the response to immune checkpoint blockade in breast cancer models. The findings highlight a novel approach leveraging nanomaterial-induced electrophysiological modulation of immune cells to overcome existing barriers in immunotherapy.

• Sisomicin: Optimizing Antibacterial Assays with a Potent Ami

  2026-07-19

  Sisomicin empowers infection modelers and clinical microbiologists with robust, reproducible inhibition of bacterial protein synthesis in both Gram-negative and Gram-positive pathogens. This guide delivers actionable workflows, advanced troubleshooting, and evidence-backed protocol enhancements to accelerate your research using APExBIO's trusted Sisomicin.

452 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page